STAT+: Popular insulin product enters shortage as other pens leave market

RegulatoryLantus SolostarNegative

AI Analysis

Summary

Lantus Solostar insulin pen is experiencing a de facto shortage despite not being on the official FDA shortage list, making it difficult for patients to obtain. Multiple insulin pens are being withdrawn from the market, contributing to supply constraints.

Outcome Details

Product shortage affecting patient access

Importance:5/10

Sentiment:

-0.60

insulinshortagesupply chainpatient access

Related Companies

$SNYNF

Read the original article

Published by STAT News on July 23, 2026 4:23 PM

Read Original